Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
Biomea Fusion has completed enrollment in its COVALENT-211 Phase II trial evaluating icovamenib in insulin-deficient type 2 diabetes patients inadequately controlled on antihyperglycemic therapies. The trial enrolled 64 patients, assessing icovamenib's ability to restore beta-cell function and provide durable glycemic control, with topline results …